These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23642696)

  • 1. Regorafenib for metastatic colorectal cancer.
    Ricotta R; Sartore-Bianchi A; Verrioli A; Vanzulli A; Siena S
    Lancet; 2013 May; 381(9877):1537. PubMed ID: 23642696
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib for metastatic colorectal cancer.
    Hyun MH; Shin MR; Kim YH
    Lancet; 2013 May; 381(9877):1537-8. PubMed ID: 23642695
    [No Abstract]   [Full Text] [Related]  

  • 3. Regorafenib for metastatic colorectal cancer.
    André T; Raymond E; de Gramont A
    Lancet; 2013 May; 381(9877):1536-7. PubMed ID: 23642693
    [No Abstract]   [Full Text] [Related]  

  • 4. Regorafenib for metastatic colorectal cancer - Authors' reply.
    Van Cutsem E; Grothey A
    Lancet; 2013 May; 381(9877):1538-9. PubMed ID: 23642697
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of regorafenib in colorectal cancer and GIST.
    Waddell T; Cunningham D
    Lancet; 2013 Jan; 381(9863):273-5. PubMed ID: 23177516
    [No Abstract]   [Full Text] [Related]  

  • 6. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 7. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 12. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
    [No Abstract]   [Full Text] [Related]  

  • 15. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
    García-Alfonso P; Feliú J; García-Carbonero R; Grávalos C; Guillén-Ponce C; Sastre J; García-Foncillas J
    Clin Transl Oncol; 2016 Nov; 18(11):1072-1081. PubMed ID: 27037815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
    Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
    Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
    Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
    Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
    Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 20. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
    Draper A
    Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.